These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 16091019)

  • 21. Who does the numbers? The role of third-party technology assessment to inform health systems' decision-making about the funding of health technologies.
    Barbieri M; Hawkins N; Sculpher M
    Value Health; 2009; 12(2):193-201. PubMed ID: 18700865
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Do reassessments reduce the uncertainty of decision making? Reviewing reimbursement reports and economic evaluations of three expensive drugs over time.
    Sandmann FG; Franken MG; Steenhoek A; Koopmanschap MA
    Health Policy; 2013 Oct; 112(3):285-96. PubMed ID: 23628483
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Methodological quality of economic evaluations of new pharmaceuticals in The Netherlands.
    Hoomans T; Severens JL; van der Roer N; Delwel GO
    Pharmacoeconomics; 2012 Mar; 30(3):219-27. PubMed ID: 22074610
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Group cognitive behavioural therapy for postnatal depression: a systematic review of clinical effectiveness, cost-effectiveness and value of information analyses.
    Stevenson MD; Scope A; Sutcliffe PA; Booth A; Slade P; Parry G; Saxon D; Kalthenthaler E;
    Health Technol Assess; 2010 Sep; 14(44):1-107, iii-iv. PubMed ID: 20863477
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Cost-effectiveness of new drugs impacts reimbursement decision making but room for improvement].
    Hoomans T; van der Roer N; Severens JL; Delwel GO
    Ned Tijdschr Geneeskd; 2010; 154():A958. PubMed ID: 20699045
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A MEA is a MEA is a MEA? Sequential decision making and the impact of different managed entry agreements at the manufacturer and payer level, using a case study for an oncology drug in England.
    Buyukkaramikli NC; Wigfield P; Hoang MT
    Eur J Health Econ; 2021 Feb; 22(1):51-73. PubMed ID: 32901420
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The HTA Risk Analysis Chart: Visualising the Need for and Potential Value of Managed Entry Agreements in Health Technology Assessment.
    Grimm SE; Strong M; Brennan A; Wailoo AJ
    Pharmacoeconomics; 2017 Dec; 35(12):1287-1296. PubMed ID: 28849538
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of economic evidence in Canadian oncology reimbursement decision-making: to lambda and beyond.
    Rocchi A; Menon D; Verma S; Miller E
    Value Health; 2008; 11(4):771-83. PubMed ID: 18179658
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Limitations of pharmacoeconomics from a clinical-pharmacological point of view].
    Müller M
    Wien Med Wochenschr; 2006 Dec; 156(23-24):619-21. PubMed ID: 17211766
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effectiveness and cost-effectiveness of computer and other electronic aids for smoking cessation: a systematic review and network meta-analysis.
    Chen YF; Madan J; Welton N; Yahaya I; Aveyard P; Bauld L; Wang D; Fry-Smith A; Munafò MR
    Health Technol Assess; 2012; 16(38):1-205, iii-v. PubMed ID: 23046909
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identifying future research priorities using value of information analyses: left atrial appendage occlusion devices in atrial fibrillation.
    Micieli A; Bennell MC; Pham B; Krahn M; Singh SM; Wijeysundera HC
    J Am Heart Assoc; 2014 Sep; 3(5):e001031. PubMed ID: 25227405
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Cost-Effectiveness of Bimodal Stimulation Compared to Unilateral and Bilateral Cochlear Implant Use in Adults with Bilateral Severe to Profound Deafness.
    Theriou C; Fielden CA; Kitterick PT
    Ear Hear; 2019; 40(6):1425-1436. PubMed ID: 30998548
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The clinical effectiveness and cost-effectiveness of technologies used to visualise the seizure focus in people with refractory epilepsy being considered for surgery: a systematic review and decision-analytical model.
    Burch J; Hinde S; Palmer S; Beyer F; Minton J; Marson A; Wieshmann U; Woolacott N; Soares M
    Health Technol Assess; 2012; 16(34):1-157, iii-iv. PubMed ID: 22985954
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The assessment and appraisal of regenerative medicines and cell therapy products: an exploration of methods for review, economic evaluation and appraisal.
    Hettle R; Corbett M; Hinde S; Hodgson R; Jones-Diette J; Woolacott N; Palmer S
    Health Technol Assess; 2017 Feb; 21(7):1-204. PubMed ID: 28244858
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Value-of-information analysis to reduce decision uncertainty associated with the choice of thromboprophylaxis after total hip replacement in the Irish healthcare setting.
    McCullagh L; Walsh C; Barry M
    Pharmacoeconomics; 2012 Oct; 30(10):941-59. PubMed ID: 22667458
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Using pharmacoeconomic analysis to make drug insurance coverage decisions.
    Anis AH; Rahman T; Schechter MT
    Pharmacoeconomics; 1998 Jan; 13(1 Pt 2):119-26. PubMed ID: 10176146
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Decision-analytical modelling in health-care economic evaluations.
    Sun X; Faunce T
    Eur J Health Econ; 2008 Nov; 9(4):313-23. PubMed ID: 17943332
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevalence of Immature Survival Data for Anti-Cancer Drugs Presented to the National Institute for Health and Care Excellence and Impact on Decision Making.
    Tai TA; Latimer NR; Benedict Á; Kiss Z; Nikolaou A
    Value Health; 2021 Apr; 24(4):505-512. PubMed ID: 33840428
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.